NCT06909695

Brief Summary

Over recent years, military service women have shown increasing interest in utilizing long-acting reversible contraceptives (LARCs; i.e., implants or intrauterine devices, IUDs). While clinically, LARC have been proven safe and effective at preventing pregnancy \& decreasing menstrual symptoms, it is unclear what impact this type of contraceptive may have on physiological responses to extreme environments (heat, cold and high altitude). Additionally, iron deficiency and iron deficiency anemia are prevalent in U.S. military women which likely affect health and performance. There is evidence to suggest that the prevalence of iron deficiency and iron deficiency anemia is lower in women utilizing LARCs, which preserve iron stores, likely due to reduced menstrual blood loss that compounds with each cycle over the course of months. Due to the increasing interest in the utilization of LARCs it is important to understand what, if any, impact these methods of contraception may have on a female Soldier's physiological responses. The overall goal of the present study is to characterize iron status and physiological responses (including but not limited to sweating, skin blood flow, ventilation, and heart rate) to extreme environmental stressors of heat, cold and high altitude (i.e. hypobaric hypoxia) in women utilizing LARCs. Up to thirty-three individuals (n=18 LARCs, n=15 monophasic oral contraceptives) will complete testing visits separated by at least 48 hours for environmental testing visits. During heat stress testing, measures of core body temperature, skin temperature, and sweat rate will be measured during a standardized protocol in hot, humid conditions. During cold stress, measures of body core temperature, metabolic heat production, skin blood flow and temperature (at both distal extremity and proximal body sites) will be assessed in order to better quantify the impact of exogenous sex hormones via LARCs and OCs in volunteers exposed to the cold. Measurements will be obtained during a standardized protocol in cold air (\~90 min; 10°C). For altitude, cardiopulmonary responses will be assessed during rest and exercise during an acute altitude exposure (4300m). Blood samples will be collected throughout the investigation in order to quantify sex hormone concentrations, iron status, and inflammatory biomarkers in response to environmental stressors. The investigators will also utilize laboratory tests (i.e., carbon monoxide (CO) rebreathing technique) and collect blood samples to quantity iron stores in these groups of women. To characterize iron status, the Soldier Performance Health and Readiness (SPHERE) epidemiological data repository will be utilized to quantify the prevalence of iron deficiency and iron deficient anemia diagnoses between women using LARCs and women not utilizing LARCs.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
33

participants targeted

Target at P25-P50 for all trials

Timeline
14mo left

Started Nov 2024

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress57%
Nov 2024Sep 2027

First Submitted

Initial submission to the registry

October 4, 2024

Completed
28 days until next milestone

Study Start

First participant enrolled

November 1, 2024

Completed
5 months until next milestone

First Posted

Study publicly available on registry

April 3, 2025

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2027

Last Updated

April 30, 2026

Status Verified

April 1, 2026

Enrollment Period

2.8 years

First QC Date

October 4, 2024

Last Update Submit

April 29, 2026

Conditions

Outcome Measures

Primary Outcomes (8)

  • Iron status

    Iron stores as measured by ferritin levels

    upon initial visit

  • Ventilation

    ventilatory response to high altitude exposure at rest and during exercise

    intermittently throughout high-altitude trial (5 timepoints overall over ~6-7 hours)

  • Thermoregulation in the heat - core temperature

    Measure of core temperature

    measured intermittently throughout trial (at least every 5 minutes) for 2 hour exposure

  • Thermoregulation in the cold - skin blood flow

    Measure of thermoregulation during resting cold stress to include skin blood flow

    measured intermittently throughout cold trial (at least every 5 minutes) for 2 hour exposure

  • Thermoregulation in the heat - skin temperature

    measured intermittently throughout trial (at least every 5 minutes) for 2 hour exposure

  • Thermoregulation in the heat - sweating rate

    Calculated from pre- and post-nude body mass corrected for fluid consumed and urine produced

    Only measured during heat stress visit, at one timepoint immediately after exercise on heat stress visit (post-exercise, within 10-20 minutes)

  • Thermoregulation in the cold - core temperature

    measured intermittently throughout cold trial (approximately every 5-10 min) for 2 hour exposure

  • Thermoregulation in the cold - skin blood flow

    measured intermittently throughout cold trial (approximately every 5-10 minutes) for 2 hour exposure

Study Arms (2)

SARC

Control group utilizing short-acting reversible contraceptives (i.e. combined oral contraceptives tested only in the active pill phase or transdermal patch)

Other: Blood volume and environmental testing

LARC users

Users of hormonal long-acting reversible contraceptives (LARCs) (e.g. hormonal IUDs, hormonal subcutaneous implants)

Other: Blood volume and environmental testing

Interventions

Testing blood volume measures, iron stores, and physiological responses to acute environmental exposures of heat, cold, and high-altitude (each environment independently)

LARC usersSARC

Eligibility Criteria

Age18 Years - 40 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsParticipant eligibility is based on self-representation of gender identity and the inclusion criteria of utilizing either combined oral contraceptives or long-acting reversible contraceptives
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

The proposed population will be healthy and active women between the ages of 18-40. This population is suitable for the purpose of this investigation since they are the most militarily relevant population (i.e., representative of the U.S. Army active duty population).

You may qualify if:

  • Females, age 18-40 y
  • Females taking monophasic oral contraceptives or utilizing implantable contraception (intrauterine device, implantable bar) for at least one year, and be at least one year removed from the removal end point (e.g. before year 4 for a 5-year IUD)
  • In good health as determined by OMSO (Office of Medical Support and Oversight)
  • Passed most recent Army Combat Fitness Test (ACFT) (military volunteers only) or exercise at least 2 times per week (civilian volunteers)
  • Willing to not drink alcoholic beverages for 24 hours before each testing session
  • Willing to not consume caffeine 12 hours prior to any testing sessions
  • Willing to refrain from any exercise and additional moderate to strenuous physical activity 24 hours prior to testing
  • Willing to stay and exercise in an altitude chamber (the size of a dorm room) for \~6 hours
  • Supervisor approval for federal civilian employees and non-HRV active-duty military personnel stationed at NSSC.

You may not qualify if:

  • Females who are pregnant, planning to become pregnant during the study, or breastfeeding.
  • Taking prescription, over the counter medication, or dietary supplements, other than a contraceptive (unless approved by OMSO and Principal Investigator (PI))
  • Tobacco or nicotine users, or anyone who has used tobacco or nicotine within the last four months
  • Physical problems/injuries (e.g., current stress fractures, musculoskeletal strains) that would affect walking or running on a treadmill
  • Allergy to skin adhesive
  • Heart, lung, kidney, muscle, endocrine, or nerve disorder(s) as determined by OMSO
  • History of heat intolerance or orthostatic intolerance
  • Diagnosed and/or treated for fluid/electrolyte imbalance within the last 30 days
  • History of obstructive disease of the gastrointestinal tract including (but not limited to) diverticulosis, diverticulitis and inflammatory bowel disease, peptic ulcer disease, Crohn's disease, ulcerative colitis.
  • Scheduled MRI within 2 weeks after completing a heat or cold test
  • Actively dieting with the intent to lose weight
  • History of cold injuries of any severity (e.g., frostbite, trench foot, chilblains).
  • Raynaud's syndrome
  • Cold-induced asthma/bronchospasm
  • Not willing to have small areas of skin on the body shaved (if deemed necessary for attachment of study instrumentation)
  • +9 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

US Army Research Institute of Environmental Medicine

Natick, Massachusetts, 01760, United States

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood samples, without DNA, for analysis of biomarkers of environmental stress

MeSH Terms

Conditions

Iron Deficiencies

Interventions

Blood Volume

Condition Hierarchy (Ancestors)

Iron Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

Blood Physiological PhenomenaCirculatory and Respiratory Physiological PhenomenaHemodynamicsCardiovascular Physiological Phenomena

Study Officials

  • Gabrielle Giersch, PhD

    United States Army Research Institute of Environmental Medicine

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Gabrielle E Giersch, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
FED
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 4, 2024

First Posted

April 3, 2025

Study Start

November 1, 2024

Primary Completion (Estimated)

September 1, 2027

Study Completion (Estimated)

September 1, 2027

Last Updated

April 30, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations